

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**WUXI BIOLOGICS (CAYMAN) INC.**

**藥明生物技術有限公司\***

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2269)**

## **VOLUNTARY ANNOUNCEMENT**

This announcement is made by WuXi Biologics (Cayman) Inc. (the “**Company**”) on a voluntary basis. Reference is made to the announcements (the “**Announcements**”) of the Company dated January 29, 2024, February 4, 2024, March 7, 2024 and May 17, 2024 in relation to the Draft Bill that has been introduced in the U.S. Congress. Unless otherwise defined herein, capitalized terms used in this announcement shall have the same meanings as those defined in the Announcements.

The Company has noted that the Draft Bill (H.R. 8333) was considered and passed by the U.S. House of Representatives (the “**House**”) after a vote on September 9, 2024 (U.S. time). The Draft Bill passed by the House was based on the version passed by the House Committee on Oversight and Accountability in May 2024 and included, among others, (i) a designation of the Company as a “biotechnology company of concern”; and (ii) a “grandfather clause” before implementing the restrictions under the proposed legislation from 2032.

As the Draft Bill must be approved by the U.S. Senate for it to become law, its contents are still subject to further review and modification during the remaining legislative process. The pending legislative path in the U.S. Senate also remains unclear at this stage.

As a global biologics CRDMO platform, the Company does not have a human genomics business, nor does it collect human genomic data in any of its businesses around the world. The Company firmly believes that it has not, does not, and will not pose a security risk to the U.S. or any other countries and strongly object to any unsubstantiated and pre-emptive designation of the Company without due process. The Company will continue to closely monitor the legislative process and engage in discussions with the relevant stakeholders. The Company remains fully committed to supporting its clients globally and operating in accordance with the applicable laws and regulations of all jurisdictions where it has business operations.

**Shareholders and potential investors of the Company should exercise caution when dealing in the securities of the Company.**

By order of the Board  
**WuXi Biologics (Cayman) Inc.**  
**Dr. Ge Li**  
*Chairman*

Hong Kong, September 10, 2024

*As at the date of this announcement, the board of directors of the Company comprises Dr. Zhisheng Chen as executive director; Dr. Ge Li, Dr. Weichang Zhou, Dr. Yibing Wu and Mr. Yanling Cao as non-executive directors; and Mr. William Robert Keller, Mr. Kenneth Walton Hitchner III, Mr. Jackson Peter Tai and Dr. Jue Chen as independent non-executive directors.*

\* *For identification purpose only*